

Amynah Amir Ali Pradhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2246544/publications.pdf>

Version: 2024-02-01

48
papers

1,773
citations

279798

23
h-index

276875

41
g-index

51
all docs

51
docs citations

51
times ranked

1685
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in migraine and headache therapy (BJP 75th anniversary). British Journal of Pharmacology, 2022, 179, 355-357.	5.4	0
2	<i>Headache</i> basic science prize. Headache, 2022, 62, 221-222.	3.9	0
3	Seq-ing the mechanisms of migraine. Neuron, 2022, 110, 1745-1746.	8.1	1
4	Migraine and peripheral pain models show differential alterations in neuronal complexity. Headache, 2022, 62, 780-791.	3.9	9
5	Delta opioid receptors in Nav1.8 expressing peripheral neurons partially regulate the effect of delta agonist in models of migraine and opioid-induced hyperalgesia. Neurobiology of Pain (Cambridge, Mass) Tj ETQq1 2022, 14, 784314 rgBT /Ove	2.0	14
6	A non-convulsant delta-opioid receptor agonist, KNT127, reduces cortical spreading depression and nitroglycerin-induced allodynia. Headache, 2021, 61, 170-178.	3.9	15
7	Delta opioid receptor regulation of calcitonin gene-related peptide dynamics in the trigeminal complex. Pain, 2021, 162, 2297-2308.	4.2	14
8	Enhanced Understanding of Molecular Interactions and Function Underlying Pain Processes Through Networks of Transcript Isoforms, Genes, and Gene Families. Advances and Applications in Bioinformatics and Chemistry, 2021, Volume 14, 49-69.	2.6	4
9	Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition. ELife, 2021, 10, .	6.0	21
10	Alternative Splicing Mechanisms Underlying Opioid-Induced Hyperalgesia. Genes, 2021, 12, 1570.	2.4	7
11	Advancing our commitment to our peer reviewers. Headache, 2021, 61, 1299-1301.	3.9	5
12	Forebrain delta opioid receptors regulate the response of delta agonist in models of migraine and opioid-induced hyperalgesia. Scientific Reports, 2020, 10, 17629.	3.3	16
13	Pain, Motivation, Migraine, and the Microbiome: New Frontiers for Opioid Systems and Disease. Molecular Pharmacology, 2020, 98, 433-444.	2.3	9
14	Differential medication overuse risk of novel anti-migraine therapeutics. Brain, 2020, 143, 2681-2688.	7.6	37
15	Acid-sensing ion channel 3 blockade inhibits durovascular and nitric oxide-mediated trigeminal pain. British Journal of Pharmacology, 2020, 177, 2478-2486.	5.4	25
16	NOP receptor agonist attenuates nitroglycerin-induced migraine-like symptoms in mice. Neuropharmacology, 2020, 170, 108029.	4.1	16
17	The development of a mouse model of mTBI-induced post-traumatic migraine, and identification of the delta opioid receptor as a novel therapeutic target. Cephalalgia, 2019, 39, 77-90.	3.9	32
18	Emerging Treatment Targets for Migraine and Other Headaches. Headache, 2019, 59, 50-65.	3.9	22

#	ARTICLE	IF	CITATIONS
19	Effect of Histone Deacetylase Inhibitor on Ethanol Withdrawal-Induced Hyperalgesia in Rats. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 523-527.	2.1	15
20	Opioid-Induced Hyperalgesia Is Associated with Dysregulation of Circadian Rhythm and Adaptive Immune Pathways in the Mouse Trigeminal Ganglia and Nucleus Accumbens. <i>Molecular Neurobiology</i> , 2019, 56, 7929-7949.	4.0	34
21	PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2447-2458.	3.8	30
22	Delta opioid receptor agonists are effective for multiple types of headache disorders. <i>Neuropharmacology</i> , 2019, 148, 77-86.	4.1	55
23	Targeted Nitric Oxide Synthase Inhibitors for Migraine. <i>Neurotherapeutics</i> , 2018, 15, 391-401.	4.4	83
24	Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. <i>Cephalalgia</i> , 2018, 38, 1471-1484.	3.9	44
25	Gene Network Dysregulation in the Trigeminal Ganglia and Nucleus Accumbens of a Model of Chronic Migraine-Associated Hyperalgesia. <i>Frontiers in Systems Neuroscience</i> , 2018, 12, 63.	2.5	27
26	Tolerance to high-internalizing μ opioid receptor agonist is critically mediated by arrestin 2. <i>British Journal of Pharmacology</i> , 2018, 175, 3050-3059.	5.4	37
27	From blast to bench: A translational mini-review of posttraumatic headache. <i>Journal of Neuroscience Research</i> , 2017, 95, 1347-1354.	2.9	20
28	A PTEN-Regulated Checkpoint Controls Surface Delivery of μ Opioid Receptors. <i>Journal of Neuroscience</i> , 2017, 37, 3741-3752.	3.6	35
29	Ligand-Directed Signaling at the Delta Opioid Receptor. <i>Handbook of Experimental Pharmacology</i> , 2017, 247, 73-85.	1.8	6
30	Delta-opioid receptors as targets for migraine therapy. <i>Current Opinion in Neurology</i> , 2016, 29, 314-319.	3.6	27
31	The delta opioid receptor tool box. <i>Neuroscience</i> , 2016, 338, 145-159.	2.3	26
32	Agonist-Specific Recruitment of Arrestin Isoforms Differentially Modify Delta Opioid Receptor Function. <i>Journal of Neuroscience</i> , 2016, 36, 3541-3551.	3.6	59
33	The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. <i>Cephalalgia</i> , 2016, 36, 1048-1056.	3.9	66
34	Cell-Autonomous Regulation of Mu-Opioid Receptor Recycling by Substance P. <i>Cell Reports</i> , 2015, 10, 1925-1936.	6.4	30
35	In Vivo Techniques to Investigate the Internalization Profile of Opioid Receptors. <i>Methods in Molecular Biology</i> , 2015, 1230, 87-104.	0.9	8
36	μ -Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. <i>British Journal of Pharmacology</i> , 2014, 171, 2375-2384.	5.4	89

#	ARTICLE	IF	CITATIONS
37	Characterization of a novel model of chronic migraine. <i>Pain</i> , 2014, 155, 269-274.	4.2	214
38	Chronic Inflammatory Injury Results in Increased Coupling of Delta Opioid Receptors to Voltage-Gated Ca ²⁺ Channels. <i>Molecular Pain</i> , 2013, 9, 1744-8069-9-8.	2.1	39
39	Select G-Protein-Coupled Receptors Modulate Agonist-Induced Signaling via a ROCK, LIMK, and β -Arrestin 1 Pathway. <i>Cell Reports</i> , 2013, 5, 1010-1021.	6.4	45
40	Evaluation of cre recombinase delivery in mammalian cells using baculovirus infection. <i>Journal of Biotechnology</i> , 2013, 166, 182-186.	3.8	3
41	Ligand-directed signalling within the opioid receptor family. <i>British Journal of Pharmacology</i> , 2012, 167, 960-969.	5.4	122
42	The delta opioid receptor: an evolving target for the treatment of brain disorders. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 581-590.	8.7	240
43	Sequential and opposing alterations of 5-HT _{1A} receptor function during withdrawal from chronic morphine. <i>European Neuropsychopharmacology</i> , 2011, 21, 835-840.	0.7	20
44	Modality of hyperalgesia tested, not type of nerve damage, predicts pharmacological sensitivity in rat models of neuropathic pain. <i>European Journal of Pain</i> , 2010, 14, 503-509.	2.8	24
45	Role of rat sensory neuron-specific receptor (rSNSR1) in inflammatory pain: Contribution of TRPV1 to SNSR signaling in the pain pathway. <i>Pain</i> , 2009, 143, 130-137.	4.2	18
46	Comparison between μ -opioid receptor functional response and autoradiographic labeling in rat brain and spinal cord. <i>Journal of Comparative Neurology</i> , 2005, 481, 416-426.	1.6	33
47	Morphine-Induced Changes in δ Opioid Receptor Trafficking Are Linked to Somatosensory Processing in the Rat Spinal Cord. <i>Journal of Neuroscience</i> , 2004, 24, 5549-5559.	3.6	68
48	Mechanisms of the Potentiation by Adenosine of Adenosine Triphosphate-Induced Calcium Release in Tracheal Smooth-Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 30-36.	2.9	18